Microglial modulation through colony-stimulating factor-1 receptor inhibition attenuates demyelination

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a leading cause of progressive disability in young adults, with limited treatments for its advanced stages.
• Microglial activation, dependent on colony-stimulating factor-1 receptor (CSF-1R) signaling, drives MS pathophysiology, including demyelination and neurodegeneration.
• Existing therapies offer limited efficacy for progressive MS, necessitating novel therapeutic strategies targeting underlying mechanisms.

Purpose of the Study:

• To evaluate the preventive and therapeutic effects of the CSF-1R inhibitor BLZ945 on demyelination, remyelination, and neurodegeneration.
• To assess the impact of microglial modulation via BLZ945 in acute and chronic cuprizone (CPZ)-induced demyelination models.
• To explore the potential of targeting CSF-1R signaling for treating progressive forms of multiple sclerosis.

Main Methods:

• Oral administration of the brain-penetrant CSF-1R inhibitor BLZ945 in acute and chronic cuprizone (CPZ) mouse models of demyelination.
• Evaluation of microglial numbers, demyelination, remyelination, and neuroprotection following BLZ945 treatment.
• Assessment of treatment effects in both preventive and therapeutic settings across different disease models.

Main Results:

• BLZ945 treatment significantly reduced microglial numbers.
• Preventive BLZ945 attenuated demyelination in the acute CPZ model, particularly in the cortex and external capsule.
• In the chronic CPZ model, both preventive and therapeutic BLZ945 promoted significant remyelination and neuroprotection, whereas efficacy was limited in acute models.
• The study observed potential impairment in myelin repair in acute models, possibly due to altered microglial function.

Conclusions:

• Modulation of microglial activity through CSF-1R inhibition with BLZ945 demonstrates therapeutic potential in chronic demyelinating conditions.
• BLZ945 shows promise for promoting remyelination and neuroprotection, particularly in chronic and progressive forms of multiple sclerosis.
• Further research is warranted to optimize BLZ945 efficacy and understand its mechanisms in different stages of demyelinating diseases.